Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kala Pharmaceuticals receives FDA complete response letter for KPI-121 0.25% NDA
Image: Kala is developing KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. Photo: courtesy of Aline Berry from Pixabay.
Image: Kala is developing KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. Photo: courtesy of Aline Berry from Pixabay.